A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A new study shows that adding niraparib to standard prostate cancer treatment slows disease progression by up to 50% in men ...

Adding PARP inhibitor niraparib to standard prostate cancer treatment delays disease progression in men with certain DNA ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing ...

Drugs already in use could be combined to form a two-pronged attack on advanced prostate cancer, a study suggests.

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

A Biden spokeswoman confirmed the former president finished several weeks of radiation therapy treatment Monday.

Former President and Penn professor Joe Biden recently completed a round of radiation therapy to treat prostate cancer at ...